Montelukast as an add-on therapy in bronchopulmonary dysplasia.
10.3345/kjp.2009.52.2.181
- Author:
He Min KIM
1
;
Ji Eun SONG
;
Soon Min LEE
;
Min Soo PARK
;
Kook In PARK
;
Ran NAMGUNG
;
Chul LEE
Author Information
1. Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea. minspark@yumc.yonsei.ac.kr
- Publication Type:Multicenter Study ; Original Article ; Clinical Trial ; Controlled Clinical Trial
- Keywords:
Bronchopulmonary dysplasia;
Montelukast;
Safety;
Efficiency
- MeSH:
Acetates;
Anti-Inflammatory Agents;
Antioxidants;
Bronchodilator Agents;
Bronchopulmonary Dysplasia;
Dependency (Psychology);
Diuretics;
Humans;
Incidence;
Infant, Newborn;
Infant, Premature;
Inflammation;
Nutritional Support;
Oxygen;
Quinolines;
Ventilation;
Ventilators, Mechanical
- From:Korean Journal of Pediatrics
2009;52(2):181-186
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Inflammation plays a potential role in the pathogenesis of bronchopulmonary dysplasia (BPD). Strategies for preventing BPD include respiratory management, antioxidants, nutritional treatment, and others such as anti-inflammatory agents. We aimed to assess the safety, tolerability, and efficacy of montelukast (MK), a cysteinyl leukotriene 1 receptor antagonist, as an add-on therapy in BPD. METHODS: In addition to currently available standard measures such as oxygen supplementation, bronchodilators, nutritional support, and/or diuretics, montelukast was administered to 15 preterm infants with BPD. MK was given orally (1 mg/kg/d) for a mean period of 12 weeks. We compared safety and efficacy parameters with historical controls. RESULTS: All 15 patients survived, and no differences were found in the incidence of adverse reactions between the 2 groups. The ventilation index was significantly improved after 2 weeks in MK group compared with historical controls. There were no significant differences in other respiratory parameters (MAP, oxygen dependency, and ventilator dependency) between the groups, but the MK group showed trends of greater improvement. CONCLUSION: Administration of MK 1 mg/kg/d was well tolerated in preterm BPD patients as an add-on therapy. We demonstrated that after 2 weeks of MK administration of 1 mg/kg/d, MK had beneficial therapeutic effects on BPD patients as an add-on to the standard therapy. Further multicenter randomized controlled clinical trials are needed to confirm the efficacy and safety of MK as a useful supplement to standard therapy for BPD patients.
